Among the 10 patients (43.5%) who remained unlisted, 9 of them (90%) were considered to have insufficient weight loss to be listed
The goal is often steadier recovery and fewer "off days," not a dramatic overnight shift
Elkind-Hirsch et al., in a 24-weeks intervention, indicated that exenatide monotherapy or its combination with MET was overall superior to MET monotherapy in terms of weight, abdominal fat, and insulin sensitivity
(126) showed that prefrontal neurons from post-mortem brain samples obtained from patients with BD and peripheral cells from patients with BD contain a larger number of smaller-sized mitochondria
Hepatology 56 , 21542162 (2012)
In phase 3 trials, after 56 weeks of treatment, 62% of patients receiving contrave 32 (bupropion SR 360 mg/naltrexone SR 32 mg) lost at least 5% of their body weight as compared to 23% of patients in the placebo group [240]